Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

496915 Oridonin, R. rubescens - CAS 28957-04-2 - Calbiochem

496915
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
28957-04-2C₂₀H₂₈O₆

Products

Catalogue NumberPackaging Qty/Pack
496915-5MGCN Plastic ampoule 5 mg
Description
OverviewA cell-permeable diterpenoid compound that possesses anti NF-κB activity and displays antiproliferative (ED50 = ~ 2.7 µg/ml in lymphoid malignant cells) and antiangiogenic properties (significantly inhibits network formation of HMEC-1 cells at 2.5 µg/ml). Reported to affect DNA synthesis, induce apoptosis and initiate cell cycle arrest. Shown to efficiently block both TNF-α and LPS-induced NF-κB activity in Jurkat and in RAW264.7 murine macrophages, and inhibit p65 NF-κB transcriptional activity (IC50 = ~ 5 µg/ml in MT-1 cells) by disrupting NF-κB DNA-binding activity without interfering with its nuclear translocation.
Catalogue Number496915
Brand Family Calbiochem®
References
ReferencesIkezoe, T., et al. 2005. Mol. Cancer Ther. 4, 578.
Meade-Tollin, L.C., et al. 2004. J. Nat. Prod. 67, 2.
Product Information
CAS number28957-04-2
ATP CompetitiveN
FormYellow solid
Hill FormulaC₂₀H₂₈O₆
Chemical formulaC₂₀H₂₈O₆
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetNF-κB transcriptional activity
Primary Target IC<sub>50</sub>5 µg/ml inhibiting p65 NF-κB transcriptional activity in MT-1 cells
Purity≥93% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSNZ8177000
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
496915-5MGCN 04055977199871

Documentation

Oridonin, R. rubescens - CAS 28957-04-2 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

Oridonin, R. rubescens - CAS 28957-04-2 - Calbiochem Certificates of Analysis

TitleLot Number
496915

References

Reference overview
Ikezoe, T., et al. 2005. Mol. Cancer Ther. 4, 578.
Meade-Tollin, L.C., et al. 2004. J. Nat. Prod. 67, 2.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision24-January-2017 JSW
DescriptionA cell-permeable inhibitor of NF-κB activity that displays antiproliferative (ED50 ~ 2.7 µg/ml in lymphoid malignant cells) and antiangiogenic properties (significantly inhibits network formation of HMEC-1 cells at 2.5 µg/ml). Reported to affect DNA synthesis, induce apoptosis, and initiate cell cycle arrest. Shown to efficiently block both TNF-α and LPS-induced NF-κB activity in Jurkat and in RAW264.7 murine macrophages. Also inhibits p65 NF-κB transcriptional activity (IC50 ~5 µg/ml in MT-1 cells) by disrupting NF-κB DNA-binding activity without interfering with its nuclear translocation.
FormYellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number28957-04-2
RTECSNZ8177000
Chemical formulaC₂₀H₂₈O₆
Structure formulaStructure formula
Purity≥93% by HPLC
SolubilityDMSO (10 mg/ml). Use only fresh DMSO for reconstitution.
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesIkezoe, T., et al. 2005. Mol. Cancer Ther. 4, 578.
Meade-Tollin, L.C., et al. 2004. J. Nat. Prod. 67, 2.